Clinical Trial ProgressBenitec Biopharma has made steady advances with the Phase 1b/2a trial of its lead clinical candidate, BB-301, with the sixth subject being safely treated with the low dose.
Efficacy And SafetyThe updated data from the Ph1/2 trial of BB-301 for dysphagia in oculopharyngeal muscular dystrophy patients provided further validation of BB-301’s safety and ability to stabilize or potentially improve swallowing profile.
Financial PerformanceBenitec Biopharma recorded a F3Q25 net loss of only $0.24 per share vs. the forecast of a net loss of $0.36 per share.